Format

Send to

Choose Destination
Immunol Lett. 2015 Apr;164(2):76-80. doi: 10.1016/j.imlet.2015.01.001. Epub 2015 Jan 24.

The role of Th17 cells in patients with relapsing-remitting multiple sclerosis: interleukin-17A and interleukin-17F serum levels.

Author information

1
Neuroscience Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Immunology Department, Medicine Faculty, Tabriz University of Medical Sciences, Tabriz, Iran; Immunology Unit, Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: zbabaloo@tbzmed.ac.ir.
2
Neuroscience Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Immunology Department, Medicine Faculty, Tabriz University of Medical Sciences, Tabriz, Iran; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
3
Immunology Department, Medicine Faculty, Tabriz University of Medical Sciences, Tabriz, Iran.
4
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
5
Immunology Department, Medicine Faculty, Tabriz University of Medical Sciences, Tabriz, Iran; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
6
Neuroscience Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Abstract

BACKGROUND AND AIMS:

Multiple sclerosis (MS) is an inflammatory condition of the central nervous system, with genetic and environmental factors having a role in its etiology. The condition is characterized by demyelination, acute inflammation, and chronic and acute lesions in the central nervous system. Human and experimental studies have shown that T-helper cells, and pro-inflammatory cytokines have a major role in the pathogenesis of MS. Recent researches have shown that IL-17 secreting T (Th17) cells have a role in inflammation and demyelination of the central nervous system. In the present study, the role of Interleukin-17A (IL-17A) and Interleukin-17F (IL-17F) in the immunopathogenesis and follow-up of the MS disease was evaluated.

MATERIALS AND METHODS:

Thirty-five relapsing remitting (RR) form of MS patients were included in the present study. Blood samples were taken from 35 MS patients and 35 healthy individuals as controls. Enzyme-Linked Immunosorbent Assay (ELISA) was used to determine IL-17A and IL-17F serum levels.

RESULTS:

A statistically significant increase was noted in the serum levels of IL-17A and IL-17F in MS patients compared to the controls (P<0.001). There was a significant positive correlation of IL-17F serum levels with the number of relapses (rs=0.717, P<0.001). However, there was no significant relationship between the serum levels of these cytokines and Expanded Standard Disability Stated Scale (EDSS) and disease Progression Index (PI).

CONCLUSION:

The data of the present study revealed a significant increase in the serum levels of IL-17A and IL-17F in MS patients compared with healthy controls and a significant positive correlation of IL-17F serum levels with the number of relapses. It appears that increased serum levels of IL-17 and especially IL-17F may lead to a raised risk of MS.

KEYWORDS:

IL-17A; IL-17F; Multiple Sclerosis; Relapsing-remitting MS; Th17

PMID:
25625963
DOI:
10.1016/j.imlet.2015.01.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center